AsclepiX Therapeutics Overview
- Status
- Private
- Latest Deal Type
- Series A
- Latest Deal Amount
- $35M
- Investors
- 13
AsclepiX Therapeutics General Information
Description
Developer of biomimetic anti-angiogenic and anti-lymphangiogenic peptides designed to transform the treatment of retinal disease and cancer through the rapid clinical development of groundbreaking therapies. The company's peptides are used for indications in ophthalmology, oncology and for other angiogenesi and lymphangiogenesis-dependent diseases, enabling patients and doctors to better treat ocular ailments.
Contact Information
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Drug Delivery
Primary Office
- 301 West 29th Street
- Suite 2004
- Baltimore, MD 21211
- United States
+1 (610) 000-0000
AsclepiX Therapeutics Timeline
AsclepiX Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC (Series A) | 24-Jun-2020 | $35M | 0000 | Completed | Generating Revenue | |
| 6. Grant | 01-Jan-2019 | 00000 | Completed | Generating Revenue | ||
| 5. Grant | 01-Jan-2017 | 00.00 | Completed | Generating Revenue | ||
| 4. Grant | 01-Sep-2015 | 00000 | Completed | Generating Revenue | ||
| 3. Grant | 24-Jul-2014 | 00.000 | Completed | Generating Revenue | ||
| 2. Accelerator/Incubator | 25-Jun-2014 | Completed | Generating Revenue | |||
| 1. Grant | 15-Jun-2013 | $100K | Completed | Generating Revenue |
AsclepiX Therapeutics Executive Team (5)
AsclepiX Therapeutics Board Members (7)
| Name | Representing | Role | Since |
|---|---|---|---|
| Ben Askew Ph.D | Self | Board Member | 000 0000 |
| Christopher Garabedian | Perceptive Advisors | Board Member | 000 0000 |
| Joshua Barer | Barer & Son Capital | Board Member | 000 0000 |
| Kevin Slawin MD | Self | Chief Executive Officer & Board Member | 000 0000 |
| Sapna Srivastava Ph.D | Self | Board Member | 000 0000 |
AsclepiX Therapeutics Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Barer & Son Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Hibiscus Capital Management | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
| Perceptive Advisors | Hedge Fund | Minority | 000 0000 | 000000 0 | |
| Piedmont Capital Partners | Merchant Banking Firm | 000 0000 | 000000 0 | ||
| Rapha Capital Management | Corporation | 000 0000 | 000000 0 |